A Crohn's disease-associated IL2RA enhancer variant determines the balance of T cell immunity by regulating responsiveness to IL-2 signaling.

Rimma GoldbergJennie N CloughLuke B RobertsJenifer SanchezShahram KordastiNedyalko PetrovArnulf HertweckAnna LorencIan JacksonScott TaskerAnna AppiosOmer OmerMiles ParkesNatalie PrescottRichard G JennerPeter M IrvingGraham M Lord

Published in: Journal of Crohn's & colitis (2021)

rs61839660 regulates the responsiveness of T cells to IL-2 signaling by modulating CD25 expression. As low dose IL-2 is being trialed as a selective Treg modulator in CD, these findings highlight the potential for adverse effects in patients with this genotype.

Keyphrases

low dose
poor prognosis
binding protein
high dose
climate change
systemic sclerosis
long non coding rna
ankylosing spondylitis